Orthopedic Soft Tissue Repair Market To Represent USD 9.4 Billion Opportunity Globally by 2024

Orthopedic soft tissue repair market is expected to be over USD 9.39 billion by 2024, based on a new report by Grand View Research, Inc. Rising demand for minimally invasive procedures has provided greater growth prospects for the market. Minimally invasive knee replacement surgery involves lesser disturbance of muscles and tendons, making the reconstruction procedure more natural.
Increasing awareness amongst the population that skeletally immature patients can also tear their connective tissue and ligaments has boosted the growth of the industry. Furthermore, rising awareness regarding the development, commercialization, and promotion of advanced platelet-rich plasma devices would fuel the market in the long run. Hence, this factor plays a pivotal role for boosting the market in the near future.
Technological advancements and innovations continue to be seen in the orthopedic connective tissue repair space. Novel advances, such as innovative surgical techniques, are also visible in the field of Anterior Cruciate Ligament (ACL) reconstruction to make these procedures more effective. Such innovations, developments, and advancements would lead to further growth of the market in the near future. Furthermore, increasing road accidents also are estimated to accentuate the demand for the market to a large extent.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/orthopedic-soft-tissue-repair-market

Further Key Findings from the Study Suggest:

 ·         Cruciate ligaments repair dominated the overall procedure segment in 2015 with revenue generation of over USD 1.9 billion owing to higher prevalence ACL injuries among athletes, as they are more prone to such type of injuries during sport-related activities. Furthermore, ACL is also a frequently occurring knee injury and the standard treatment for this disorder is surgical reconstruction.

·         Knee segment held the largest industry share in 2015, because it is a frequently affected target injury location among the athletes as well as the geriatric population base. Bones as well as connective tissues, such as tendons, ligaments, and cartilages naturally weaken with growing in age. This poses greater risk for occurrence of target injuries, mainly in knees of the elderly population.

·         Posterior soft tissue repair is one of the common procedures in total hip arthroplasty. Soft tissue injuries surrounding the hip joints result in dysfunction of the joint. As a result of this, hip segment is estimated to attain a lucrative CAGR of over 7.5% over the forecast period.

·         North America contributed toward the largest industry share of around USD 2.0 billion in 2015. The primary factors favoring this growth include investments for developed healthcare infrastructure. This has led to advancements in soft tissue repair surgeries, such as minimally invasive procedures. Moreover, majority of the key players are headquartered in the U.S., which provides a wide market for orthopedic soft tissue repair.

·         Asia Pacific is anticipated to witness highest CAGR over the forecast period owing to greater penetration of medical devices in countries like Japan and increasing geriatric population in India.

·         The key players serving orthopedic soft tissue repair market include Stryker, Zimmer Biomet, Smith & Nephew Plc, Arthrex, Inc., CONMED, and DePuy Synthes, Inc.

·         Strategic collaborations, mergers & acquisitions, widening the distribution network, and technological advancements are some of the key strategies the companies are concentrating on in order to enhance the market demand for orthopedic soft tissue repair.

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented the orthopedic soft tissue repair market on the basis of procedure and injury location:
Procedure Outlook (Revenue in USD Million, 2013 - 2024)

·         Rotator cuff repair

·         Epicondylitis

·         Achilles tendinosis repair

·         Pelvic organ prolapsed

·         Gluteal tendon repair

·         Cruciate ligaments repair

·         Hip arthroscopy

·         Biceps tenodesis

·         Others

Injury Location Outlook (Revenue in USD Million, 2013 - 2024)

·         Knee

·         Shoulder

·         Hip

·         Small joints

Regional Outlook (Revenue in USD Million, 2013 - 2024)

·         North America

o    U.S.

o    Canada

·         Europe

o    UK

o    Germany

·         Asia Pacific

o    Japan

o    China

o    India

·         Latin America

o    Brazil

o    Mexico

·         Middle East and Africa

o    South Africa

For press release of this report - http://www.grandviewresearch.com/press-release/global-orthopedic-soft-tissue-repair-market

Point Of Care Diagnostics Market To Represent USD 20.9 Billion Opportunity Globally by 2024

The global point of care (PoC) diagnostics market is anticipated to reach USD 20.9 billion by 2024, according to a new report by Grand View Research, Inc. Rise in the R&D funding and research activities amongst the market players in order to introduce novel POC tests and devices for ease of disease detection and monitoring is expected to fuel industrial progress through to 2024.
Moreover, the introduction of favorable regulatory initiatives in order to promote the development and adoption of POC diagnostic tests is anticipated to propel growth in the coming years. Furthermore, advancement of diagnostic laboratories and adaptation of more integrated and automated lab systems are also factors expected to fuel demand for advanced workflow systems and drive the digital pathology and workflow segment through to 2024.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/point-of-care-poc-diagnostics-industry

Further key findings from the report suggest:

·         Glucose testing accounted for the largest share in revenue in 2015 owing to the higher prevalence of diabetes. Presence of significant product portfolio pertaining to glucose testing in the market and the presence of a number of major players as wells as local manufacturers from different regions are factors attributive to contribute substantially to the revenue generated.

·         Hb1Ac POC tests are more reliable for glucose testing and due to the vast patient base for diabetes management, this segment is second in terms of revenue generation in the POC market only to its counterpart. Owing to the presence of glucose testing segment as a potential market and growing cost effectiveness of Hb1Ac tests, it is expected that over the coming decade it will witness considerable growth in demand and usage 

·         POC tests for infectious disease testing, is another segment of prime activity in the point of care industry. This segment includes rapid diagnostic tests for a considerable number of diseases including HIV, HBV, RSV, HPV, Influenza, HCV, MRSA, TB/dr-TB & HSV among others.

·         Owing to the growing incidence of a number of infectious diseases, initiatives taken by a number of governments to implement early diagnosis and screening, and development of rapid tests able to distinguish between a wide number of pathogens this segment has been observed to be at the demand receiving end in the industry for the better half of the last decade and is only expected to witness growth in demand.

·         Hospitals are estimated to be the dominant end-users for POC diagnosis industry owing to higher penetration of products and comparatively higher usage rate for disease monitoring and diagnosis.

·         North America dominated the market in 2015, with over 43% of total revenue. Presence of major entities with widespread distribution network coupled with significant number of research endeavors carried out in the U.S is supportive for the largest share of region. Moreover, point of care diagnostics is a relatively more advanced segment of in vitro diagnostics and owing to the presence of high R&D expenditure, availability of a technologically advanced healthcare infrastructure along with the presence of a number of ongoing government funded research projects are factors accounting for the region’s large share.

·         Asia Pacific is projected to witness lucrative growth in the coming years owing to the developments carried out in developing economies herein in order to develop the healthcare infrastructure and reduce the incidence of target diseases.

·         Major participants of this market include Roche, Abbott Laboratories, Siemens Healthcare, Danaher Corporation, BioMerieux, Johnson & Johnson, Abaxis Inc., Alere Inc., Qiagen N.V., Spectral Diagnostics, Instrumentation Laboratory, Nova Biomedical, Nipro Diagnostics, Trinity Biotech, and Sekisui.

·         Participants are involved in adopting competitive strategies in order to enhance the market presence. These companies are also involved in collaborations with hospitals in order to maintain the market share.

·         For instance, in April 2015, Nipro diagnostics participated in an industry event named AMCP (Academy of Managed Care Pharmacy) in support of providing care to the patients with diabetes.

Read detailed report or request for sample of this research report: - http://www.grandviewresearch.com/industry-analysis/point-of-care-poc-diagnostics-industry/request

Grand View Research has segmented point of care diagnostics market on the basis of application, end-use, and region:
Global Point of Care Diagnostics Outlook, by Product (Revenue, USD Million, 2013 - 2024)

·         Glucose Testing

·         Hb1Ac Testing

·         Infectious Disease Testing

·         HIV POC

·         Clostridium difficile POC

·         HBV POC

·         Pneumonia or Streptococcus associated infections

·         Respiratory syncytial virus (RSV) POC

·         HPV POC

·         Influenza/Flu POC

·         HCV POC

·         MRSA POC

·         TB and drug-resistant TB POC

·         HSV POC

·         Other Infectious Diseases

·         Coagulation

·         Fertility

·         Cardiac markers

·         Primary care systems

·         Hematology

·         Decentralized Clinical Chemistry

·         Feces

·         Blood Gas/Electrolytes

·         Ambulatory Chemistry

·         Urinalysis

·         Drug Abuse Testing

Global Point of Care Diagnostics Outlook, by End-use (Revenue, USD Million, 2013 - 2024)

·         Clinics

·         Hospitals

·         Assisted Living Healthcare Facilities

·         Laboratory

·         Others

Point of Care Diagnostics Regional Outlook (Revenue, USD Million, 2013 - 2024)

·         North America

·         U.S.

·         Canada

·         Europe

·         Germany

·         UK

·         Spain

·         France

·         Italy

·         Asia Pacific

·         China

·         Japan

·         India

·         Singapore

·         Korea

·         Australia

·         Latin America

·         Brazil

·         Mexico

·         Argentina

·         Chile

·         MEA

·         South Africa

·         Nigeria

·         Kenya

·         UAE

·         Saudi Arabia

·         Qatar

·         Zimbabwe

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/clinical-diagnostics

Molecular Cytogenetics Market Size To Reach $3.6 Billion By 2022: Grand View Research, Inc.

Global molecular cytogenetics market is expected to reach nearly USD 3.6 billion by 2022, according to a new report by Grand View Research, Inc.
Increasing instances of both, chromosomal anomalies implicated in genetic disorders and cancer, coupled with technological advancements in the molecular cytogenetic techniques is expected to positively reinforce the market growth.
Technological advancements in molecular diagnostic techniques, such as the Fluorescence In-situ Hybridization (FISH) and the Comparative Genomic Hybridization (CGH) are enabling rapid analysis of patient data to identify the potential risk factors. Increasing applications of FISH and CGH in molecular diagnostics are expected to propel the market growth in the next seven years.
The advent of the genome wide screening technique, the Next Generation Sequencing (NGS) technology enables the detection of a number of chromosomal variations in parallel by comparing genomic sequences of patient and control samples.
The NGS technique empowers the clinicians in taking therapeutic decisions based on in-depth information regarding an individual’s genetic profile; and hence, the introduction of such technologies is expected to positively reinforce the market growth during the forecast period. Initiatives such as the precision medicine initiative announced by the U.S. president are expected to further drive the demand for the molecular cytogenetic tests.
In 2014, the CGH in the technology segment held the maximum market share of 52% owing to enhanced technical specifications such as high speed, accuracy, and high resolution images as compared to the FISH technology. Furthermore, the CGH technology is also expected be the fastest growing segment with a lucrative CAGR of nearly 26% over the forecast period.
In 2014, the application of molecular cytogenetics in cancer held the largest market share of over 42%. The high demand for preventive screening and diagnosis, which significantly aids the early detection of risk factors that lead to oncogenesis, are amongst the key factors responsible for the cancer segment’s high share. Cancer was followed by the personal medicine segment with a market share of over 23%. In conclusion, the cancer segment is expected to be the fastest growing market with a high CAGR of 24.1% over the forecast period.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/molecular-cytogenetics-market

Further key findings from the study suggest:

·         In 2014, North America held the largest market share of 47.6%. The large share is attributed to the presence of high-tech R&D facilities, well established manufacturing infrastructure, and active collaborations between private stakeholders, such as technology companies, research centers, universities, patients, as well as government agencies such as the U.S. FDA and CDC that ensure that the new technologies are validated.

·         Asia Pacific is expected to witness lucrative CAGR of nearly 26% in the next seven years owing to the high unmet medical needs such as the increasing prevalence of cancer, genetic, and other hereditary diseases.

·         Key factors contributing to the swift growth ar the rapid development in fast growing Asian economies such as India, China, and others, the increasing healthcare expenditure to improve R&D activities, rapid proliferation of advanced diagnostic technologies, and the increasing awareness about the genetic and molecular screening tests; these crucial factors are expected to synergistically propel the market growth over the forecast period.

·         The global molecular cytogenetics market is dominated by players such as Abbott Laboratories Inc., Illumina, Inc., Agilent Technologies, Inc., Applied Spectral Imaging, Inc., PerkinElmer, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., and others.

Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/biotechnology

Grand View Research has segmented the global molecular cytogenetics market on the basis of technology outlook, application outlook, and regional outlook.
Global Molecular Cytogenetics Market, Technology Outlook (Revenue, USD Million, 2012 - 2022)

·         FISH

·         CGH

Global Molecular Cytogenetics Market, Technology Outlook (Revenue, USD Million, 2012 - 2022)

·         Genetic Disorders

·         Cancer

·         Personalized Medicine

·         Others

Global Molecular Cytogenetics Market, Regional Outlook (Revenue, USD Million, 2012 - 2022)

·         North America

·         Europe

·         Asia Pacific

·         RoW

For press release of this report - http://www.grandviewresearch.com/press-release/global-molecular-cytogenetics-market